TNG260は小分子CoREST阻害剤で,STK11変異腫瘍を抗PD-1免疫療法に敏感にする
Leanne G Ahronian1, Soumyadip Sahu2, Minjie Zhang3
1Tango Therapeutics (United States), Boston, MA, United States.
Cancer research
|August 29, 2025
まとめ
STK11変異性非小細胞肺がん (NSCLC) は,抗PD-1治療に耐性がある. HDAC1をTNG260で標的にすると,この抵抗性が逆転し,前臨床および臨床試験で抗PD-1の有効性が強化された.
科学分野:
- 腫瘍学
- 免疫療法
- 分子生物学
背景:
- 非小細胞肺がん (NSCLC) のSTK11の喪失は,抗PD-1のような免疫チェックポイント阻害剤 (ICI) に対する耐性を授与する.
- 新しい治療標的を特定することは,STK11変異性NSCLCにおけるICI耐性を克服するために極めて重要です.
研究 の 目的:
- 抗PD-1療法に対するSTK11喪失による抵抗を逆転させる標的を特定する.
- CoREST複合体を標的とした新しい治療薬であるTNG260の開発と評価
主な方法:
- 抗PD-1抵抗を逆転させる標的を特定するために in vivo CRISPRスクリーンを実施した.
- CoREST複合体の小分子阻害剤であるTNG260を開発した.
- 臨床前NSCLCモデルと第1相臨床試験 (NCT05887492) で,抗PD-1と併用してTNG260を評価した.
主要な成果:
- HDAC1は,STK11喪失媒介の抗PD-1抵抗を克服する重要な標的として特定されました.
- TNG260は,STK11欠乏した癌細胞における免疫調節遺伝子発現を増加させ,CoREST複合体の有力かつ選択的阻害を示した.
- TNG260と抗PD-1を併用した治療は,臨床前モデルの腫瘍静止/ 逆行を引き起こし,患者の腫瘍におけるヒストンアセチル化,PD- L1発現,T細胞浸透が増加した.
結論:
- TNG260でHDAC1を標的にすることは,STK11変異性NSCLCを抗PD-1治療に再敏感化するための有望な戦略です.
- TNG260と抗PD-1の組み合わせは,腫瘍の微小環境を調節することによって,抗腫瘍免疫を強化します.
- このアプローチは,通常,現在の免疫療法に弱い反応を示すSTK11変異性NSCLCの患者にとって,潜在的な新しい治療法を提供します.
さらに関連する動画
関連する概念動画
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K


